CEO Of Rain Therapeutics On The Company's Developments In Cancer Treatment

Rain Therapeutics (RAIN) is a clinical-stage precision oncology company. They recently went public in 2021. Co-founder and CEO, Avanish Vellanki, speaks about Rain Therapeutics’ internal growth potential as well as the effect that its new treatment Rain-32 will have. Vellanki states that Rain-32 has been seen to triple or quadruple the survival time of patients with difficult to treat cancer. Rain Therapeutics is continuing to build a pipeline of targeted cancer therapies. Tune in to find out more.

The Watch List

01 Jun 2021

ON AIR
7:00 am
Futures

Get Market Minute

Daily insights for every investor

FOLLOW US

CEO Of Rain Therapeutics On The Company's Developments In Cancer Treatment

Rain Therapeutics (RAIN) is a clinical-stage precision oncology company. They recently went public in 2021. Co-founder and CEO, Avanish Vellanki, speaks about Rain Therapeutics’ internal growth potential as well as the effect that its new treatment Rain-32 will have. Vellanki states that Rain-32 has been seen to triple or quadruple the survival time of patients with difficult to treat cancer. Rain Therapeutics is continuing to build a pipeline of targeted cancer therapies. Tune in to find out more.

The Watch List

01 Jun 2021